See more : Kingfisher Metals Corp. (KFR.V) Income Statement Analysis – Financial Results
Complete financial analysis of Lexaria Bioscience Corp. (LEXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexaria Bioscience Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- School Specialty, LLC (SCOO) Income Statement Analysis – Financial Results
- Aiphone Co.,Ltd. (6718.T) Income Statement Analysis – Financial Results
- Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ) Income Statement Analysis – Financial Results
- Prolific Technology Inc. (6233.TWO) Income Statement Analysis – Financial Results
- Taiwan Semiconductor Manufacturing Company Limited (TSFA.F) Income Statement Analysis – Financial Results
Lexaria Bioscience Corp. (LEXX)
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.28K | 226.21K | 255.40K | 722.74K | 384.54K | 222.61K | 433.29K | 63.64K | 40.72K | 14.70K | 1.10M | 1.36M | 1.13M | 362.47K | 421.96K | 900.79K | 253.15K | 20.31K | 20.31K |
| Cost of Revenue | 4.82K | 31.50K | 71.84K | 175.35K | 99.38K | 22.89K | 25.19K | 29.75K | 45.62K | 29.88K | 795.20K | 783.27K | 667.86K | 273.62K | 548.32K | 912.75K | 124.91K | 93.32K | 93.32K |
| Gross Profit | 459.46K | 194.71K | 183.56K | 547.39K | 285.17K | 199.72K | 408.10K | 33.89K | -4.90K | -15.18K | 302.25K | 574.49K | 465.91K | 88.86K | -126.37K | -11.96K | 128.24K | -73.01K | -73.01K |
| Gross Profit Ratio | 98.96% | 86.07% | 71.87% | 75.74% | 74.16% | 89.72% | 94.19% | 53.25% | -12.03% | -103.26% | 27.54% | 42.31% | 41.09% | 24.51% | -29.95% | -1.33% | 50.66% | -359.55% | -359.55% |
| Research & Development | 2.36M | 3.67M | 1.84M | 1.26M | 387.07K | 555.73K | 492.86K | 54.19K | 9.02K | 146.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.85M | 3.06M | 5.72M | 4.97M | 3.57M | 3.13M | 6.02M | 1.63M | 1.01M | 1.49M | 1.27M | 561.89K | 678.09K | 466.67K | 458.04K | 475.34K | 1.01M | 121.44K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 204.28K | 515.36K | 489.06K | 209.03K | 185.46K | 276.56K | 8.19K | 3.47K | 40.92K | 559.00 | 930.00 | 4.11K | 20.07K | 20.07K | 0.00 |
| SG&A | 3.85M | 3.06M | 5.72M | 4.97M | 3.77M | 3.64M | 6.51M | 1.84M | 1.20M | 1.76M | 8.19K | 565.35K | 719.01K | 467.23K | 458.97K | 479.45K | 1.03M | 141.51K | 35.14K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 112.75K | 60.55K | 2.31K | -886.00 | 4.60K | -22.66K | 0.00 | 14.04K | 6.40K | 0.00 | 8.21K | 1.28K | 148.38K | -2.99K | 0.00 |
| Operating Expenses | 6.21M | 6.73M | 7.57M | 6.23M | 4.27M | 4.26M | 7.01M | 1.90M | 1.21M | 1.91M | 8.19K | 579.40K | 725.41K | 474.00K | 467.18K | 480.72K | 1.18M | 138.53K | 35.14K |
| Cost & Expenses | 6.22M | 6.76M | 7.64M | 6.41M | 4.37M | 4.28M | 7.03M | 1.92M | 1.26M | 1.94M | 803.40K | 1.36M | 1.39M | 747.61K | 1.02M | 1.39M | 1.30M | 231.85K | 35.14K |
| Interest Income | 14.31K | 43.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.00 | 4.09K | 18.09K | 6.12K | 6.12K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02K | 2.25K | 31.54K | 267.36K | 246.61K | 278.73K | 167.32K | 160.12K | 857.58K | 4.71K | 21.91K | 21.91K |
| Depreciation & Amortization | 76.15K | 145.40K | 146.91K | 147.60K | 146.09K | 60.55K | 2.31K | 1.49K | 619.00 | -22.66K | 1.52M | 456.60K | 370.62K | 122.16K | 342.13K | 453.12K | 148.38K | 81.76K | 40.44K |
| EBITDA | -5.68M | -6.39M | -6.52M | -5.58M | -4.00M | -4.10M | -6.61M | -1.92M | -1.26M | -1.95M | 294.06K | -35.30K | 442.73K | 111.12K | -236.15K | -244.37K | -414.37K | -891.03K | -129.78K |
| EBITDA Ratio | -1,222.75% | -2,824.23% | -2,835.72% | -977.11% | -982.78% | -1,752.23% | -1,522.76% | -2,922.37% | -2,983.84% | -13,269.46% | 26.79% | 33.27% | 9.80% | -72.55% | -59.58% | 37.67% | -356.22% | 730.49% | 26.11% |
| Operating Income | -5.75M | -6.53M | -7.38M | -5.69M | -3.89M | -3.96M | -6.60M | -1.86M | -1.22M | -1.93M | 294.06K | -4.90K | -259.50K | -552.46K | -753.67K | -898.09K | -1.05M | -489.66K | -35.14K |
| Operating Income Ratio | -1,239.16% | -2,888.50% | -2,891.05% | -786.85% | -1,012.10% | -1,779.43% | -1,523.29% | -2,924.71% | -2,985.36% | -13,115.30% | 26.79% | -0.36% | -22.89% | -152.42% | -178.61% | -99.70% | -414.83% | -2,411.28% | -173.02% |
| Total Other Income/Expenses | -55.52K | -178.50K | -764.61K | 1.52M | 0.00 | -228.06K | -8.97K | -6.02K | -34.70K | -55.06K | -355.23K | -246.61K | -276.22K | -278.73K | 0.00 | 7.05K | -73.27K | -565.19K | -473.12K |
| Income Before Tax | -5.81M | -6.71M | -7.38M | -4.16M | -4.08M | -4.16M | -6.61M | -1.93M | -1.28M | -1.98M | -1.87M | -251.51K | -538.23K | -552.46K | -753.67K | -971.35K | -1.05M | -211.54K | -75.58K |
| Income Before Tax Ratio | -1,251.12% | -2,967.41% | -2,891.05% | -576.16% | -1,062.20% | -1,868.03% | -1,525.36% | -3,031.89% | -3,136.82% | -13,489.80% | -170.50% | -18.52% | -47.47% | -152.42% | -178.61% | -107.83% | -416.69% | -1,041.70% | -372.16% |
| Income Tax Expense | 0.00 | 0.00 | -114.33K | -1.66M | -54.29K | 39.62K | -8.97K | -54.17K | -60.23K | -181.23K | 294.06K | 246.61K | 278.73K | 167.32K | -94.00 | 7.14K | 1.04K | 574.84K | 40.59K |
| Net Income | -5.80M | -6.66M | -7.27M | -2.50M | -4.03M | -4.20M | -6.60M | -1.87M | -1.21M | -1.77M | -1.87M | -251.51K | -538.23K | -552.46K | -753.57K | -978.49K | -1.06M | -508.26K | -75.72K |
| Net Income Ratio | -1,248.25% | -2,946.36% | -2,846.28% | -346.50% | -1,048.08% | -1,885.83% | -1,522.97% | -2,937.31% | -2,983.38% | -12,042.58% | -170.50% | -18.52% | -47.47% | -152.42% | -178.59% | -108.63% | -417.10% | -2,502.87% | -372.89% |
| EPS | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| EPS Diluted | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| Weighted Avg Shares Out | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
| Weighted Avg Shares Out (Dil) | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study
DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained higher levels of semaglutide in blood; Faster achievement of peak drug delivery; and Reduced side effects. KELOWNA, BC / ACCESSWIRE / November 27, 2023...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ),...
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded Minimum ongoing payments, royalties and manufacturing revenues part of the agreement KELOWNA, BC / ACCESSWIRE / October 13, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a...
Lexaria Granted Two New Patents in Canada
Lexaria now holds 37 granted patents world-wide Potential application in treating nicotine addiction KELOWNA, BC / ACCESSWIRE / October 12, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has...
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
KELOWNA, BC / ACCESSWIRE / September 29, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional...
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as: Reduced side effects; Enhanced weight loss; Improved health outcomes for diabetes and other conditions; Improved oral bioavailability; Reduced cost. KELOWNA, BC / ACCESSWIRE / September 21, 2023 / Lexaria...
Lexaria Provides Update on Investigational New Drug Application Progress
KELOWNA, BC / ACCESSWIRE / August 30, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this update on the status of the Company's anticipated submission of an Investigational New...
Lexaria Bioscience Corp: A Comprehensive Stock Price Change Analysis
Lexaria Bioscience Corp ( LEXX , Financial), a biotechnology company, has seen significant changes in its stock price over the past three months. With a current market cap of $9.062 million and a stock price of $1.12, the company has...
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
DehydraTECH-Nicotine reaches maximum blood saturation levels faster than world-leading brands from Swedish Match and Altria in human study NIC-H22-1 Noteworthy superior subjective performance characteristics also observed KELOWNA, BC / ACCESSWIRE / August 9, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...
Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to report its intention to conduct a human clinical study to examine DehydraTECH-CBD for...
Source: https://incomestatements.info
Category: Stock Reports